Overview

Ilomedin Treatment for Patients Having Undergone Primary Percutaneous Coronary Intervention (PCI)

Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
Acute myocardial infarct patients with STEMI (ST-elevation on ECG) whom undergo a primary percutaneous cardiac intervention will following the standard treatment , received low dose of Ilomedin and to low dose of standard treatment for another 24 hours.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Thrombologic ApS
Collaborators:
Lene Holmvang
Rigshospitalet, Denmark
Treatments:
Iloprost